Credit: Getty Images New research is being conducted on factor XI inhibitor therapy as the patent expiration for factor Xa inhibitors nears. Factor XI inhibitor therapy research is being conducted as ...

The anticoagulant reversal drug Andexxa was voluntarily pulled from the US market after failing to secure full FDA approval ...

A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...

"[...] this is the first study to address the effects of Xa-Is on composite cardiovascular events, congestive heart failure, arteriosclerotic disease, and ...

Acute intracerebral hemorrhage may occur in patients on factor Xa inhibitors. The efficacy and safety of the FXa inhibitor reversal agent andexanet for limiting ICH volume expansion are unknown. New ...

After today, andexanet alfa (Andexxa; AstraZeneca) will no longer be made or sold in the United States, according to an alert from the US Food and Drug Administration.

AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US in light of FDA concerns ...

If you’re experiencing severe side effects from the blood thinner warfarin, a doctor may recommend an alternative known as non-vitamin K oral anticoagulants (NOACs). Non-vitamin K oral anticoagulants ...

Andexanet alfa (Andexxa) will officially be taken off the U.S. market this month as an emergency reversal medication for ...